IRB# 5307: CyberKnife Prostate Study

Prospective Evaluation of CyberKnife® as Monotherapy or Boost Stereotactic Body Radiotherapy for Intermediate or High Risk Localized Prostate Cancer: An Observational Study

FAQ

Frequently Asked Questions

1 Why is this study being done?

The purpose of this study is to document the effects of CyberKnife® radiosurgery in patients with intermediate or high risk prostate cancer and to evaluate the effects of the therapy on patients' quality of life over a five year period.

2 Will I still receive medical care if I decide to not participate in the study?

Yes. The information collected for the study will be used to see how helpful this treatment is to patients with prostate cancer and to look at the effects this treatment has on patients' quality of life over time. This information could help future cancer patients.

3 Will CyberKnife® treatments be covered by my insurance?

Yes. We work with your insurance to make sure you are pre-authorized for treatment however, any co-pay or deductible will be the patient's responsibility.

4 Will I need to complete additional procedures for the study?

No. You will be given the same medical testing recommendations as someone who is not on the study. Tests and assessments that are ordered by your physician are used to develop your treatment plan. As part of the study, your medical and personal information will be collected. This is part of your medical files, only de-identified information will be used for study data analysis. When you return for follow up, you will be asked to complete survey questions to assess how this treatment may have affected your quality of life.

5 How long do I have to be in the study?

Treatment can last anywhere from 3 days to 5 weeks. The length of treatment will depend on the type of prostate cancer you have.

After you complete your treatment, your study doctor will ask you to visit the office for follow-up exams for five years. During this five year period, we will keep track of your health and also observe the long-term effects of the study therapy. You are free to withdraw from this study at any time by notifying the principal investigator for this study, Arica Hirsch, MD at 847-723-8030.

This is not intended as a substitute for medical advice from your professional healthcare provider. Contact your professional healthcare provider to find out if CyberKnife® is right for you.